GLPG
Galapagos N.V. NASDAQ Listed Feb 27, 2012$27.71
Mkt Cap $1.8B
52w Low $24.74
22.8% of range
52w High $37.78
50d MA $30.45
200d MA $32.17
P/E (TTM)
5.8x
EV/EBITDA
3.2x
P/B
0.6x
Debt/Equity
0.0x
ROE
—
P/FCF
-9.1x
RSI (14)
—
ATR (14)
—
Beta
0.15
50d MA
$30.45
200d MA
$32.17
Avg Volume
142.8K
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Generaal De Wittelaan L11 A3 · Mechelen, C9 2800 · BE
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -1.14 | 0.25 | +122.0% | 28.81 | -1.0% | -3.7% | — | — | — | — | — |
| Feb 23, 2026 | AMC | 1.00 | 16.38 | +1538.0% | 33.87 | +5.5% | +1.4% | -1.0% | -1.6% | +0.5% | +1.3% | — |
| Nov 5, 2025 | AMC | -0.20 | -3.59 | -1696.3% | 29.89 | +1.7% | +4.4% | +1.1% | +2.9% | +1.2% | -1.6% | — |
| Jul 23, 2025 | AMC | -0.67 | -1.89 | -182.3% | 33.29 | -13.4% | -7.3% | +5.8% | +0.4% | +0.1% | +1.4% | — |
| Apr 23, 2025 | AMC | -0.23 | -2.47 | -973.9% | 25.50 | +0.2% | +3.9% | +1.4% | +0.0% | +0.2% | +0.0% | — |
| Feb 28, 2025 | AMC | -0.24 | 0.39 | +263.3% | 26.08 | +2.5% | -0.3% | -1.0% | +1.3% | +1.9% | +0.1% | — |
| Oct 30, 2024 | AMC | -0.27 | -0.77 | -185.2% | 28.59 | -5.8% | -7.5% | +1.7% | -0.7% | +0.1% | +1.0% | — |
| Sep 12, 2024 | AMC | 0.03 | 0.14 | +450.3% | 29.30 | +0.5% | +2.9% | +1.7% | -0.4% | -0.9% | +0.5% | — |
| May 2, 2024 | AMC | -0.12 | 0.39 | +425.0% | 29.45 | -1.2% | -1.2% | +1.3% | -1.3% | -0.2% | -0.9% | — |
| Feb 23, 2024 | AMC | -1.18 | 2.39 | +302.5% | 36.24 | -0.0% | +0.7% | +0.7% | -1.8% | -2.7% | +0.0% | — |
| Nov 3, 2023 | AMC | -0.62 | 0.39 | +162.9% | 37.06 | +5.0% | +2.8% | -0.1% | -3.6% | -1.2% | +0.2% | — |
| Aug 3, 2023 | AMC | -0.70 | 0.08 | +111.4% | 42.20 | +4.2% | +0.4% | -4.6% | -3.6% | -0.6% | +2.4% | — |
| May 4, 2023 | AMC | -0.87 | 0.43 | +149.4% | 40.50 | +2.9% | +5.9% | -2.1% | -0.3% | +0.1% | -1.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $34.36 | $34.42 | +0.2% | -1.0% | -1.6% | +0.5% | +1.3% | -3.1% |
| Nov 7 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $31.20 | $31.91 | +2.3% | +1.1% | +2.9% | +1.2% | -1.6% | -2.5% |
| Oct 22 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $31.43 | $32.19 | +2.4% | +1.4% | +0.5% | -0.2% | -2.8% | +0.9% |
| Oct 21 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $34.39 | $32.05 | -6.8% | -8.6% | +1.4% | +0.5% | -0.2% | -2.8% |
| Feb 14 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $25.49 | $25.15 | -1.3% | -0.2% | +4.3% | +0.6% | +0.1% | +0.0% |
| Jan 23 | Barclays | Downgrade | Equal Weight → Underweight | — | $23.93 | $23.56 | -1.5% | -0.8% | -0.2% | -0.4% | -0.5% | -1.4% |
| Nov 1 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $26.44 | $26.75 | +1.2% | +1.7% | -0.7% | +0.1% | +1.0% | +1.7% |
| Apr 22 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $29.08 | $28.96 | -0.4% | -0.0% | +1.3% | -2.3% | -0.5% | +0.5% |
| Apr 1 | BofA Securities | Downgrade | Neutral → Underperform | — | $32.20 | $32.06 | -0.4% | +0.9% | -2.2% | +0.1% | +0.1% | +0.0% |
| Mar 28 | BofA Securities | Downgrade | Neutral → Underperform | — | $32.95 | $32.18 | -2.3% | -2.3% | +0.9% | -2.2% | +0.1% | +0.1% |
| Jan 2 | BofA Securities | Maintains | Neutral → Neutral | — | $40.65 | $40.60 | -0.1% | +1.7% | -0.4% | +0.6% | -0.3% | +2.8% |
| Aug 7 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $42.36 | $42.42 | +0.1% | -4.6% | -3.6% | -0.6% | +2.4% | -0.9% |
| Aug 1 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $42.35 | $42.00 | -0.8% | -0.8% | -0.5% | +1.0% | +0.4% | -4.6% |
| Jul 31 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $41.82 | $41.57 | -0.6% | +1.3% | -0.8% | -0.5% | +1.0% | +0.4% |
| Jul 24 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $42.98 | $42.48 | -1.2% | -2.1% | -2.2% | -0.3% | -1.5% | +3.5% |
| Jul 17 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $41.79 | $42.34 | +1.3% | +0.3% | +1.4% | +0.4% | -0.2% | +0.9% |
| Jun 26 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $41.00 | $41.22 | +0.5% | -1.1% | +1.0% | -1.5% | +0.2% | +0.7% |
| Jun 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $43.04 | $41.40 | -3.8% | -1.9% | -0.4% | -1.1% | +2.0% | -0.1% |
| May 31 | JP Morgan | Maintains | Neutral → Neutral | — | $42.14 | $41.35 | -1.9% | -1.9% | -0.9% | +1.1% | +0.9% | +1.3% |
| May 9 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $41.99 | $41.18 | -1.9% | -0.3% | +0.1% | -1.7% | -1.6% | +3.7% |
| May 8 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $42.89 | $42.60 | -0.7% | -2.1% | -0.3% | +0.1% | -1.7% | -1.6% |
| May 8 | Raymond James | Upgrade | Market Perform → Outperform | — | $42.89 | $42.60 | -0.7% | -2.1% | -0.3% | +0.1% | -1.7% | -1.6% |
| Feb 27 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $38.19 | $38.03 | -0.4% | -1.2% | -0.6% | +0.4% | -2.6% | +0.5% |
| Feb 27 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $38.19 | $38.03 | -0.4% | -1.2% | -0.6% | +0.4% | -2.6% | +0.5% |
| Jan 23 | Jefferies | Upgrade | Underperform → Hold | — | $45.82 | $47.06 | +2.7% | +0.9% | -2.5% | -1.1% | +0.1% | -0.9% |
| Nov 7 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $42.75 | $41.09 | -3.9% | -3.5% | -0.3% | -2.5% | +3.4% | +0.8% |
| Nov 7 | Raymond James | Downgrade | Outperform → Market Perform | — | $42.75 | $41.09 | -3.9% | -3.5% | -0.3% | -2.5% | +3.4% | +0.8% |
| Nov 7 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $42.75 | $41.09 | -3.9% | -3.5% | -0.3% | -2.5% | +3.4% | +0.8% |
| Oct 13 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $42.10 | $41.90 | -0.5% | +2.6% | +0.6% | +2.6% | +2.3% | -3.7% |
| Sep 9 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $48.57 | $48.80 | +0.5% | -0.8% | +8.0% | -5.4% | -0.4% | -0.8% |
| Aug 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $54.25 | $54.56 | +0.6% | +1.7% | -1.0% | -1.7% | -2.7% | -0.2% |
| Aug 8 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $54.70 | $54.56 | -0.3% | -1.1% | -1.5% | +2.5% | -0.8% | +0.1% |
| Jul 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $52.89 | $53.32 | +0.8% | +1.7% | +0.4% | +4.9% | -0.4% | -0.3% |
| May 9 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $59.66 | $59.31 | -0.6% | -5.2% | +2.1% | -1.9% | +1.1% | +3.4% |
| Feb 28 | Morgan Stanley | Maintains | Overweight → Overweight | — | $65.74 | $65.39 | -0.5% | +0.7% | +0.1% | -2.8% | -3.8% | -0.8% |
| Jan 27 | Citigroup | Upgrade | Neutral → Buy | — | $53.32 | $61.63 | +15.6% | +22.5% | +3.3% | +0.1% | +1.5% | -4.1% |
| Jan 6 | Morgan Stanley | Maintains | Overweight → Overweight | — | $51.75 | $52.09 | +0.7% | +0.2% | -0.0% | -1.0% | +2.1% | -0.7% |
| Nov 8 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $54.28 | $55.96 | +3.1% | +5.2% | -1.2% | -3.8% | -1.6% | -1.1% |
| Aug 19 | Barclays | Downgrade | Overweight → Equal Weight | — | $59.07 | $57.78 | -2.2% | -4.4% | -1.9% | +3.4% | -0.3% | -0.2% |
| Aug 9 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $60.14 | $58.87 | -2.1% | -1.1% | -0.5% | -1.1% | +0.6% | -0.3% |
| May 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $75.04 | $71.11 | -5.2% | -2.0% | +0.1% | +0.7% | +2.6% | +0.2% |
| Apr 14 | Barclays | Upgrade | Equal Weight → Overweight | — | $78.30 | $81.51 | +4.1% | +2.8% | -1.4% | -0.3% | -0.4% | +1.1% |
| Mar 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $82.41 | $83.28 | +1.1% | +1.3% | -1.3% | +0.8% | -1.4% | -1.6% |
| Feb 22 | Raymond James | Upgrade | Market Perform → Outperform | — | $86.28 | $83.56 | -3.2% | -0.7% | -0.4% | -0.9% | +0.6% | -3.0% |
| Jan 19 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $100.01 | $106.53 | +6.5% | +7.7% | +0.7% | +3.2% | -0.7% | +0.1% |
| Nov 19 | Maxim Group | Maintains | Buy → Buy | — | $123.95 | $123.01 | -0.8% | -0.5% | +1.0% | +0.5% | -1.4% | -2.2% |
| Oct 21 | Goldman Sachs | Downgrade | Neutral → Sell | — | $131.79 | $123.35 | -6.4% | -6.6% | +0.5% | +3.2% | -0.3% | +0.6% |
| Oct 13 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $148.25 | $147.01 | -0.8% | -1.6% | -2.2% | -2.8% | -7.0% | +1.2% |
| Aug 25 | Jefferies | Downgrade | Buy → Hold | — | $134.83 | $129.64 | -3.8% | -2.3% | +1.8% | -2.8% | +0.4% | +1.7% |
| Aug 24 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $137.16 | $136.48 | -0.5% | -1.7% | -2.3% | +1.8% | -2.8% | +0.4% |
No insider trades available.
Data updated apr 26, 2026 10:41am
· Source: massive.com